Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

E

Vanda expects its operating cash spend to be approximately $3.8 million for the first quarter of 2009, including $0.8 million for severance payments. The projected $3 million of non-severance costs include administrative overhead, personnel costs, costs to complete an ongoing carcinogenicity study and regulatory consulting fees.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to ob
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... ... effective ways to make organic gardening simple, safe and fun. , ... Boston, MA (PRWEB) October 19, 2009 -- It,s no ... vegetables naturally. As a matter of fact, "as the demand for healthy, fresh fruits and ...
... Institute for Materials Science in Japan has been chosen for ... his research in atomic-scale precision. The results of ... the production of hydrogen fuel. This year,s prize ... Palo Alto, California along with a prize for theory. Both ...
... increasing evidence that, with best intent, current biological technology ... populations, with vaccines against emerging diseases at a rate ... change, e.g., before the disease has come and gone. ... synthesized vaccines produced in seven days can be effective, ...
Cached Biology Technology:The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 2The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 3Researcher honored for experimental work in nanotechnology 2New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution 2New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution 3
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2
... be considered pests, but beaver can help mitigate the ... from wetlands to accommodate industrial, urban and agricultural demands ... Alberta study. Removal of beaver should be considered ... and industrial water extraction, said researcher Glynnis Hood, lead ...
... higher intakes of calcium and vitamin D from foods, and ... hypertension or high blood pressure, according to a new study ... After examining the diets of nearly 30,000 middle-aged and older ... milk and milk products and had diets higher in calcium ...
... Pennsylvania and the Northeast, scientists at Penn State and ... the nation,s honeybees and other pollinators, which are critical ... in the United States. To assist in this effort, ... support honeybee research and education. Haagen-Dazs has announced ...
Cached Biology News:Beavers can help ease drought 2Drinking milk may help ease the pressure 2Haagen-Dazs gift to support Penn State honeybee research 2Haagen-Dazs gift to support Penn State honeybee research 3
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
... Sequencing Quality 96 Well BAC ... template preparation from 1.5ml 2xYT ... for automated fluorescent sequencing for ... Utilizes ProPrep strategy which minimizes ...
...
Biology Products: